Windlas Biotech Limited (NSE:WINDLAS)

Market Cap	18.20B -8.7%
Revenue (ttm)	9.42B +18.5%
Net Income	664.44M +1.9%
EPS	31.13 +1.2%
Shares Out	20.64M
PE Ratio	28.33
Forward PE	n/a
Dividend	6.30 (0.71%)
Ex-Dividend Date	Jul 16, 2026

Volume	64,422
Open	900.40
Previous Close	900.40
Day's Range	859.50 - 900.40
52-Week Range	697.40 - 1,181.90
Beta	0.26
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,385
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WINDLAS

Financial Performance

In fiscal year 2026, Windlas Biotech's revenue was 9.04 billion, an increase of 18.98% compared to the previous year's 7.60 billion. Earnings were 664.56 million, an increase of 8.95%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error